Stewart Geary | Senior Vice President, Chief Medical Officer, Director, Corporate Medical Affairs Headquarters
Eisai | Japan

Stewart Geary, Senior Vice President, Chief Medical Officer, Director, Corporate Medical Affairs Headquarters, Eisai

E. Stewart Geary, M.D, has worked at Eisai since 1996 in pharmacovigilance, clinical safety and regulatory science. He is currently a member of the Executive Committee of the Japanese Association of Pharmaceutical Medicine and serves on the Editorial Advisory Boards for the publications Applied Clinical Trials and Pharmaceutical Medicine. He recently joined the CIOMS Working Group on Drug-Induced Liver Injury and served on the CIOMS VII Working Group on the Development Safety Update Report, the CIOMS VIII Working Group on Signal Detection, the CIOMS Working Group on Standardized MedDRA Queries and the CIOMS IX Working Group on Medicinal Product Risk Management.

Dr Geary graduated from Harvard College summa cum laude with a bachelor’s degree in chemistry in 1985. He spent a year doing basic research on insulin-like growth factor receptors at Harvard Medical School before attending Stanford Medical School from which he earned an MD degree in 1990. He went on to complete a residency in Urology at the Stanford University Medical Center in 1996. He lectures at several universities on Pharmaceutical Medicine and has published on the Japanese pharmaceutical industry and on global pharmaceutical regulations.


Phar-East Day Two @ 15:15

Good Pharmacovigilance Practice (GVP): What can Asia learn from the EMA?

The EMA has recently set up a new chapter in its guidelines dedicated to good pharmacovigilance practices.  This is a measurement designed to ensure a robust system for safety monitoring, to protect patients’ interests. What are the similar guidelines in Asia and what can we learn from GVP when running biosimilar trials in Asia? Should GVP be a compulsory practice in Asia?

Phar-East Day Two @ 15:55

Panel discussion: Using Real World Evidence (RWE) to support the rational use of medicine in Asia

  • Practicality issues in using RWE in Asia
  • Challenges and opportunities of regulatory innovation for SME pharma companies
  • RWE on emerging therapeutics: Key challenges and opportunities

back to speakers